Anticancer Efficiency of Reovirus in Normoxia and Hypoxia Cited by

Fol. Biol. 2013, 59, 68-75

https://doi.org/10.14712/fb2013059020068

Anticancer Efficiency of Reovirus in Normoxia and Hypoxia

K. Figová, J. Hraběta, Tomáš Eckschlager

Department of Paediatric Haematology and Oncology, Charles University in Prague – Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic

Received November 2012
Accepted January 2013

Crossref Cited-by Linking

Vazifehmand Reza, Ali Dhuha Saeed, Othman Zulkefley, Chau De-Ming, Stanslas Johnson, Shafa Mehdi, Sekawi Zamberi: The evaluation expression of non-coding RNAs in response to HSV-G47\u2206 oncolytic virus infection in glioblastoma multiforme cancer stem cells. J. Neurovirol. 2022, 28, 566. <https://doi.org/10.1007/s13365-022-01089-w>
Shayan Sara, Arashkia Arash, Azadmanesh Kayhan: Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?. Cancer Cell Int 2022, 22. <https://doi.org/10.1186/s12935-022-02774-w>
Hotani Takuma, Mizuguchi Hiroyuki, Sakurai Fuminori: Systemically Administered Reovirus-Induced Downregulation of Hypoxia Inducible Factor-1\u03b1 in Subcutaneous Tumors. Molecular Therapy Oncolytics 2019, 12, 162. <https://doi.org/10.1016/j.omto.2018.12.012>
Chakrabarty Romit, Tran Hue, Selvaggi Giovanni, Hagerman Allison, Thompson Brad, Coffey Matt: The oncolytic virus, pelareorep, as a novel anticancer agent: a review. Invest New Drugs 2015, 33, 761. <https://doi.org/10.1007/s10637-015-0216-8>